$33.65−0.13 (−0.38%)
At close: Oct 1, 2026, 4:00 PM ET
Immunovant Inc · Overview
Industry: Health Services · see every company filed here →
Immunovant Inc scores 35/100. Weak. Strongest on financial health, quality is the soft spot versus 400 Healthcare peers. Insufficient inputs: Tenet 35 is built from 3 of 4 pillars, from 30% of its inputs. The pillars showing a dash had no data.
Tenet Score · vs sector
n=400Weak
Fundamental composite — rates the business, not the timing.
Each metric's standing vs the company's own record is shown on the Statistics tab.
Value19
Quality14
Health72
Growth—
Factor grades
Grid rings: 25 · 50 · 75 · 100 percentile
Growth omitted — no data yet.
Growth omitted — no data yet.
ValueFQualityFHealthBGrowth—MomentumA
A grade is a label over the shown score. Value/Quality/Health/Growth are sector percentiles; Momentum ranks 12−1 return across the equity universe — a lens, never folded into the Tenet Score.
Price
Loading chart…
P/E
—
no P/E on file
P/B
9.5×
cap ÷ Jun 30, 2026 book value, Oct 1, 2026 close
P/S
—
no P/S on file
ROE
−80%
TTM through Jun 30, 2026
Operating margin
—
no operating margin on file
Net margin
—
no net margin on file
Current ratio
7.27
Jun 30, 2026 balance sheet
Net debt / EBITDA
—
negative EBITDA denominator
EPS CAGR 5y
—
needs five years of positive earnings
Market cap
$7.0B
mid cap
Div yield
—
no yield on file
52-wk range
15.95 – 45.42
low → high
Market cap: share price × the latest quarter's diluted weighted-average share count (vendor).
The whole report, at a glance · every card is a live peek, click any to open the section
Tenets
0 / 17
- ✕ Piotroski F-Score
- ~ Drawdown Context
- ✕ Reversal Evidence
- ✕ Not-a-Value-Trap Gate
- ✕ Quality Floor
- ~ Qualified Dip
+11 more →
Financials
Revenue, margins and the five-year statements.Analyst Forecasts
Consensus estimates are on the Analyst tab.
Earnings
Report dates and the beat-versus-miss record.Statistics
ROIC−77%
Technical Analysis
Mixed short-term signalvs 50-day−14.3%
vs 200-day+6.1%
RSI (14)29
News & Insights
Headlines are on the News tab.Dividends
Pays no dividend. Every dollar of profit is reinvested into the business.Ownership
54% institutional
13F flows & insider trades land here.
About Immunovant Inc
Immunovant, Inc., a clinical-stage biopharmaceutical company, develops monoclonal antibodies for the treatment of autoimmune diseases. It develops IMVT-1401, a novel fully human monoclonal antibody that selectively binds to and inhibits the neonatal fragmen…
Composite computed 2026-10-02 · peer basis: Healthcare (n=400) · every glimpse links to its full section with sources · not investment advice.
ETF exposure
Free account: the funds that hold IMVT, and at what weight. Everything else on this page stays open.Create a free account